Deep Expertise in Cardiorenal Drug Development
We bring many years of experience in cardiorenal drug development and mechanistic modeling of hypertension, CKD, and heart failure. This includes deep knowledge of the nuances and unique challenges in managing these complex patients.
Domain Knowledge
- Comprehensive understanding of kidney diseases and heart failure physiology/pathophysiology
- Deep knowledge of cardiorenal therapy pharmacology, including mechanisms of action and drug interactions
- Extensive literature expertise spanning experimental studies through Phase 3 trials
- Nuanced understanding of key biomarkers, their interpretation, and limitations
Technical & Practical Experience
- 16+ years developing and applying mechanistic models in pharmaceutical R&D
- Proven track record in translating complex physiology into actionable models
- Experience working with pharmacometricians, clinical pharmacologists, and R&D teams
- Understanding of regulatory requirements and expectations for modeling submissions
Therapeutic Areas
Our cardiorenal drug development expertise spans key Cardio-Kidney-Metabolic conditions, with particular specialization in:
- Hypertension
- Chronic Kidney Disease (CKD)
- Heart failure with reduced ejection fraction (HFrEF)
- Heart failure with preserved ejection fraction (HFpEF)
- Cardiorenal syndrome
- Hyperkalemia and other electrolyte and fluid imbalances
Virtual Populations & Digital Twins
We have developed and validated virtual populations for hypertension, CKD, HFrEF, and HFpEF. These populations can be used as digital twins that capture the complexity of real patient populations. Our models account for:
- Disease progression and comorbidities
- Demographic and physiological variability
- Treatment response heterogeneity
- Long-term outcomes and safety profiles
Standard-of-Care & Combination Therapy
Our models incorporate comprehensive knowledge of established cardiorenal therapies, including:
- RAAS inhibitors (ACE inhibitors, ARBs, renin inhibitors)
- SGLT2 inhibitors
- Diuretics (loop and thiazide)
- Calcium channel blockers and beta blockers
- Mineralocorticoid receptor antagonists
- ARNIs and endothelin antagonists
This expertise enables accurate simulation of combination therapies and assessment of novel drug candidates in the context of standard care.
